Pricing Log in Create free account

Aclaris Therapeutics, Inc. (ACRS) vs Shattuck Labs, Inc. (STTK)

Aclaris Therapeutics, Inc. and Shattuck Labs, Inc. are both Biotechnology companies. Aclaris Therapeutics, Inc. and Shattuck Labs, Inc. are of similar size ($550.5M and $549.0M). Shattuck Labs, Inc. grew revenue faster over the last twelve months: 106.5% against −51.0%. Shattuck Labs, Inc. has the higher net margin (0.00% vs −921.5%) and the lower return on invested capital (−1,230.7% vs −163.4%). Across the 17 metrics below, Shattuck Labs, Inc. leads on 11 and Aclaris Therapeutics, Inc. on 6.

Valuation

Metric ACRS STTK Biotechnology median
P/E n/m n/m 10.64
P/S 64.95 126.40 9.59
P/B 4.29 3.36 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales 55.12 89.24 9.45
Earnings yield (15.51%) (9.34%) (34.69%)
Free cash flow yield (11.65%) (5.82%) (24.02%)

Profitability

Metric ACRS STTK Biotechnology median
Gross margin 12.90% 100.00% 65.59%
Operating margin (1,050.16%) 0.00% 0.00%
Net margin (921.50%) 0.00% 0.00%
Free cash flow margin (756.50%) 0.00% 0.00%
Return on equity (59.10%) (39.21%) (51.96%)
Return on assets (41.07%) (36.88%) (46.06%)
Return on invested capital (163.35%) (1,230.74%) 0.00%

Growth

Metric ACRS STTK Biotechnology median
Revenue growth (TTM) (51.04%) 106.48% 4.59%
EPS growth (last fiscal year) 69.01% 53.02% 29.88%
Revenue growth, 5-year CAGR 3.84% (36.82%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACRS STTK Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.46 27.59 4.86
Net debt to EBITDA 1.20 1.62 1.01

Dividend

Metric ACRS STTK Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric ACRS STTK Biotechnology median
Market cap 550.53m 548.98m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack